Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study.

Kostikas K, Greulich T, Mackay AJ, Lossi NS, Aalamian-Mattheis M, Nunez X, Pagano VA, Patalano F, Clemens A, Vogelmeier CF.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00243-2018. doi: 10.1183/23120541.00243-2018. eCollection 2019 Feb.

2.

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.

Frent SM, Chapman KR, Larbig M, Mackay A, Fogel R, Gutzwiller FS, Shen S, Patalano F, Banerji D, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):43-51. doi: 10.1164/rccm.201801-0038OC.

3.

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

Anzueto AR, Kostikas K, Mezzi K, Shen S, Larbig M, Patalano F, Fogel R, Banerji D, Wedzicha JA.

Respir Res. 2018 Jun 20;19(1):121. doi: 10.1186/s12931-018-0830-z.

4.

Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.

Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-339. doi: 10.1164/rccm.201803-0405OC.

5.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

6.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

7.

Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations.

Mackay AJ, Kostikas K, Murray L, Martinez FJ, Miravitlles M, Donaldson G, Banerji D, Patalano F, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):730-738. doi: 10.1164/rccm.201712-2482CI.

8.

Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.

Kostikas K, Aalamian-Mattheis M, Pagano VA, Nunez X, Fogel R, Patalano F, Clemens A.

COPD. 2018 Apr;15(2):185-191. doi: 10.1080/15412555.2018.1445213. Epub 2018 Apr 16. Erratum in: COPD. 2018 Jun;15(3):313.

PMID:
29658810
9.

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD.

Kostikas K, Brindicci C, Patalano F.

Curr Drug Targets. 2018;19(16):1882-1896. doi: 10.2174/1389450119666180212120012.

10.

Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.

Donohue JF, Jones PW, Bartels C, Marvel J, D'Andrea P, Banerji D, Morris DG, Patalano F, Fogel R.

Pulm Pharmacol Ther. 2018 Apr;49:11-19. doi: 10.1016/j.pupt.2017.12.005. Epub 2017 Dec 19. Review.

PMID:
29277690
11.

Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):968-969. doi: 10.1164/rccm.201710-2027LE. No abstract available.

PMID:
29140725
12.

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR.

Am J Respir Crit Care Med. 2018 May 1;197(9):1223-1226. doi: 10.1164/rccm.201709-1822LE. No abstract available.

PMID:
29099609
13.

Indacaterol/glycopyrronium: a dual bronchodilator for COPD.

Banerji D, Fogel R, Patalano F.

Drug Discov Today. 2018 Jan;23(1):196-203. doi: 10.1016/j.drudis.2017.10.015. Epub 2017 Oct 24. Review.

PMID:
29079130
14.

Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.

Ferguson GT, Taylor AF, Thach C, Wang Q, Schubert-Tennigkeit AA, Patalano F, Banerji D.

Chronic Obstr Pulm Dis. 2016 Aug 18;3(4):716-728. doi: 10.15326/jcopdf.3.4.2016.0131.

15.

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators.

Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.

16.

Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1230-1231. doi: 10.1164/rccm.201706-1105LE. No abstract available.

17.

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 17;12:907-922. doi: 10.2147/COPD.S130482. eCollection 2017. Review.

18.

Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 May 1;195(9):1189-1197. doi: 10.1164/rccm.201701-0193OC.

19.

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.

Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:339-349. doi: 10.2147/COPD.S125058. eCollection 2017.

20.

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.

Vogelmeier C, Zhong N, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 14;11:3189-3197. doi: 10.2147/COPD.S116786. eCollection 2016.

21.
22.

The asthma-COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?

Kostikas K, Clemens A, Patalano F.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 16;11:1297-306. doi: 10.2147/COPD.S107307. eCollection 2016. Review.

23.

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.

LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, D'Andrea P.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 8;11:1233-43. doi: 10.2147/COPD.S100445. eCollection 2016.

24.

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators.

N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.

25.

Prediction and prevention of exacerbations and mortality in patients with COPD.

Kostikas K, Clemens A, Patalano F.

Expert Rev Respir Med. 2016 Jul;10(7):739-53. doi: 10.1080/17476348.2016.1185371. Epub 2016 May 20. Review.

PMID:
27135786
26.

Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study.

Kerwin E, Siler TM, Korenblat P, White A, Eckert JH, Henley M, Patalano F, D'Andrea P.

Chronic Obstr Pulm Dis. 2016 Mar 28;3(2):549-559. doi: 10.15326/jcopdf.3.2.2015.0157.

27.

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.

Banerji D, Patalano F.

Respir Med. 2016 Jan;110:79-80. doi: 10.1016/j.rmed.2015.07.009. Epub 2015 Jul 17. No abstract available.

28.

FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.

Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, Lloyd M, Patalano F, Banerji D.

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1068-79. doi: 10.1164/rccm.201505-1048OC.

PMID:
26177074
29.

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D; LANTERN Investigators.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 5;10:1015-26. doi: 10.2147/COPD.S84436. eCollection 2015.

30.

Addressing unmet needs in the treatment of COPD.

Patalano F, Banerji D, D'Andrea P, Fogel R, Altman P, Colthorpe P.

Eur Respir Rev. 2014 Sep;23(133):333-44. doi: 10.1183/09059180.00004014. Review.

31.

Recent advances in COPD disease management with fixed-dose long-acting combination therapies.

Bateman ED, Mahler DA, Vogelmeier CF, Wedzicha JA, Patalano F, Banerji D.

Expert Rev Respir Med. 2014 Jun;8(3):357-79. doi: 10.1586/17476348.2014.910457. Epub 2014 May 7. Review.

PMID:
24802656
32.

The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease.

Compton C, McBryan D, Bucchioni E, Patalano F.

Pulm Pharmacol Ther. 2013 Oct;26(5):562-73. doi: 10.1016/j.pupt.2013.05.009. Epub 2013 Jun 4. Review.

33.

A comparison of dose-response curves in cognitive-behavioral and psychodynamic psychotherapies.

Warner LK, Herron WG, Javier RA, Patalano F, Sisenwein F, Primavera LH.

J Clin Psychol. 2001 Jan;57(1):63-73.

PMID:
11211289
34.

Psychosocial stressors and the short life spans of legendary jazz musicians.

Patalano F.

Percept Mot Skills. 2000 Apr;90(2):435-6.

PMID:
10833735
35.

Injection of anti-IgE antibodies will suppress IgE and allergic symptoms.

Patalano F.

Allergy. 1999 Feb;54(2):103-10. Review. No abstract available.

PMID:
10221432
36.

Effects of serial position on Bender-Gestalt errors using Koppitz's criteria.

Nyfield B, Patalano F.

Psychol Rep. 1998 Dec;83(3 Pt 2):1227-37.

PMID:
10079721
37.

Cross-cultural similarities in the personality dimensions of heroin users.

Patalano F.

J Psychol. 1998 Nov;132(6):671-3. No abstract available.

PMID:
9857503
38.

MMPI diagnostic classification of substance abusers of the 1970s.

Patalano F.

Psychol Rep. 1998 Apr;82(2):505-6.

PMID:
9621727
39.

The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W, Kilchherr E, Staehelin T, Davis F, Gordon W, Sun L, Liou R, Wang G, Chang TW, Holgate S.

J Clin Invest. 1997 Mar 1;99(5):879-87.

40.

Psychosocial stressors in the lives of great jazz musicians.

Patalano F.

Percept Mot Skills. 1997 Feb;84(1):93-4.

PMID:
9132738
41.

Narcissism and hostility.

Patalano F.

Psychol Rep. 1997 Feb;80(1):289-90.

PMID:
9122339
42.

Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells.

Marini M, Carpi S, Bellini A, Patalano F, Mattoli S.

Biochem Biophys Res Commun. 1996 Mar 27;220(3):896-9.

PMID:
8607863
43.

Inducibility of RANTES mRNA by IL-1beta in human bronchial epithelial cells is associated with increased NF-kappaB DNA binding activity.

Manni A, Kleimberg J, Ackerman V, Bellini A, Patalano F, Mattoli S.

Biochem Biophys Res Commun. 1996 Mar 7;220(1):120-4.

PMID:
8602829
44.

Time course of IL1 and IL6 synthesis and release in human bronchial epithelial cell cultures exposed to toluene diisocyanate.

Mattoli S, Colotta F, Fincato G, Mezzetti M, Mantovani A, Patalano F, Fasoli A.

J Cell Physiol. 1991 Nov;149(2):260-8.

PMID:
1660901
45.

Effects of familiar proctor on fifth and sixth grade students' test anxiety.

DeRosa A, Patalano F.

Psychol Rep. 1991 Feb;68(1):103-13.

PMID:
2034755
46.

Nedocromil sodium prevents the release of 15-hydroxyeicosatetraenoic acid from human bronchial epithelial cells exposed to toluene diisocyanate in vitro.

Mattoli S, Mezzetti M, Fasoli A, Patalano F, Allegra L.

Int Arch Allergy Appl Immunol. 1990;92(1):16-22.

PMID:
2174022
47.

Nedocromil sodium: a review of clinical studies.

Ruggieri F, Patalano F.

Eur Respir J Suppl. 1989 Jun;6:568s-571s. Review.

PMID:
2553034
48.

Sodium cromoglycate: a review.

Patalano F, Ruggieri F.

Eur Respir J Suppl. 1989 Jun;6:556s-560s. Review.

PMID:
2508649
49.
50.

Comparison of the performance of two mini peak flow meters.

Pistelli R, Fuso L, Muzzolon R, Bevignani G, Patalano F, Ciappi G.

Respiration. 1989;56(1-2):103-9.

PMID:
2532382

Supplemental Content

Loading ...
Support Center